**Supplemental Figure 1. Synergistic effects of PD-1 and CTLA-4 blockade in enhancing antitumor abscopal effects.**  The primary tumors (5 x105) were treated with 15 Gy on day 8 after tumor injection. Anti-PD-1 mAb (Clone G4), anti-CTLA-4 mAb (Clone 9H10), or control Ig (200 ug/mouse) were intraperitoneally injected alone or as a combination of anti-PD-1 and anti-CTLA-4 antibodies on day 7 and every other day thereafter for a total of 5 doses. Tumor growth was measured in primary and secondary tumors and was shown as mean size ± SD of five mice per group. \* p<0.05 compared with mice treated with anti-PD-1 or anti-CTLA-4 alone (n=5).